insights_auto
Miks on NOVOBN tõusnud? 5,67%?
Uurige põhjalikumaltchevron_right
NOVOBN:BMV
Novo Nordisk A/S
764,50 MX$
arrow_upward
+5,67%(+41,00) 1 p
16. okt, 14:00:00 GMT −6 · MXN
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse NOVOBN põhistatistika genereerimine…
Ava
728,00 MX$
Kõrge
764,50 MX$
Madal
728,00 MX$
Turu kapit.
132,00 mld
Keskm. maht
386,00
Maht
21,00
52 näd kõrgeim
1 149,99 MX$
52 näd madalaim
630,00 MX$
Töötajate arv
67 tuh
Ava
728,00 MX$
Kõrge
764,50 MX$
Madal
728,00 MX$
Turu kapit.
132,00 mld
Keskm. maht
386,00
Maht
21,00
52 näd kõrgeim
1 149,99 MX$
52 näd madalaim
630,00 MX$
Töötajate arv
67 tuh
Uudised
Veebiallikatest ja uudistepartneritelt
Simply Wall Street
·
14 tunni eest
Novo Nordisk (NVO) Stock May Be Undervalued As Buybacks Continue
The Motley Fool
·
1 päeva eest
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Yahoo Finance
·
1 päeva eest
Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
TradingKey
·
2 päeva eest
Novo Nordisk A/S Stock (NVO) Moved Up by 3.38% on Oct 15: What Investors Need To Know
Profiil
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Teave üksuse Novo Nordisk A/S kohta
TegevjuhtMike Doustdar
Töötajad66,7 tuh
Asutatud1923
PeakontoridBagsværd, Pealinna piirkond, Taani
Sektor-
Veebisaitnovonordisk.com